Press Coverage
Graziano Seghezzi tells Unquote that after Apollo deal, "We will continue to build on our strategy"
Related Deal lead
Graziano SeghezziRachel Lewis of Unquote was among those characterizing Sofinnova Partners' deal with Apollo as part of a trend, saying Apollo was "becoming the latest large ticket house to swoop into life sciences."
But she was quick to point out that unlike Carlyle's purchase of Abingworth or the LSP purchase of EQT, there was never any chance Sofinnova Partners would be bought in full.
"We are the largest independent platform in Europe and we wanted to remain as such," Managing Partner Graziano Seghezzi told the reporter. "The coming together of private equity and venture capital is a very important movement for our industry, to grow we wanted to be in sync with that macro movement."
Seghezzi added that Sofinnova Partners would retain its culture and independence — as well as its Paris headquarters.
"We are not going to change our strategy," Seghezzi said. "We wanted to retain our business model, our business plan, and our operations. We will continue to build on our strategy."
Related News
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZITM, the First and Only Combination Eye Drop Approved to Treat Presbyopia
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials